Aehr Test Systems has had a powerful run in 2026, yet the real question for anyone looking at the stock today is whether that share price can be supported by the cash it is expected to generate over time. With the business now closely tied to demand for testing gear used in AI processors, the discussion quickly comes back to how much cash flow those opportunities may realistically translate into.
-
The stock is up 193.8% year to date, which puts a lot of weight on the assumptions sitting behind its cash flow profile.
-
Recent record sales tied to its FOX wafer-level burn in platform and a higher long term revenue outlook can shift expectations for both the level and timing of future cash generation.
-
If you'd rather focus on sales, this one's for you. See why Aehr Test Systems's 42.5x P/S tells a different valuation story .
The issue now is whether the current US$65.11 share price can be explained by Aehr Test Systems' cash flows when viewed through a Discounted Cash Flow (DCF) lens.
If you are weighing Aehr Test Systems against other ways to play this theme, it can help to compare it directly with 53 AI infrastructure stocks .
Does Aehr Test Systems Look Undervalued on Cash Flow?
The Discounted Cash Flow (DCF) approach here projects what Aehr Test Systems might return to shareholders in future and brings those cash flows back into today's dollars. On the latest twelve month numbers the business is still burning cash, with free cash flow of about $5.5 million outflow. Yet the model assumes that picture shifts into clear positive territory over the next several years.
Forecasts in this DCF point to growing annual free cash flows in the tens and then hundreds of millions of $ over the coming decade, which is a big swing from the recent outflow and asks a lot of the AI test equipment opportunity. Because Aehr Test Systems recently reported record Q1 fiscal 2027 revenue of $33.0 million and lifted its full year outlook to $150 million, the richer projections in the cash flow model line up with management leaning into that demand, even though the current US$65.11 share price still reflects a market view that differs from the model's implied worth. Find out what Aehr Test Systems could be worth using our Discounted Cash Flow (DCF) estimate .
The Aehr Test Systems Narrative: What Would Justify Today's Price?
Simply Wall St Narratives pick up where the Aehr Test Systems valuation puzzle leaves off by spelling out which specific paths for growth, margins and earnings would need to play out for the stock to be worth meaningfully more or less than today's price. Each scenario anchors its number to a clear view of how Aehr Test Systems' prospects and risks might evolve, giving you something concrete to revisit as fresh information comes through.
Community views on Aehr Test Systems split sharply between those who see early AI and silicon carbide exposure as an opportunity and those who focus on insider selling and dilution.
Bull case: 41% undervalued
"Although early work with major NAND flash and DRAM producers, including high bandwidth memory and high bandwidth flash, points to a possible new category for wafer level burn in..."
Discover why this Narrative puts Aehr Test Systems at 41% undervalued .
Bear case: 256% overvalued
"Heavy insider selling, repeated dilution, and weakening fundamentals raise serious questions about shareholder alignment..."
Explore why this Narrative puts Aehr Test Systems at 256% overvalued .
Before you act on Aehr Test Systems' valuation, there is one more piece to check
Price and cash flow only tell part of the story for Aehr Test Systems, since recent research has also highlighted specific risk checks that could change how you weigh the opportunity. Take a closer look at 2 warning signs (1 major) before settling on a valuation.
This article is general in nature and was produced with the assistance of AI automation, based on data and analysis from Simply Wall St. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include AEHR .
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
